IRulya Therapeutics presents LAM-001 Phase 2a data in pulmonary hypertension
IRLA•IRulya Therapeutics outlined trial milestones for inhaled rapamycin LAM-001, including Phase 2 data expected in the first quarter of 2027 for bronchiolitis obliterans syndrome and Phase 2b data expected in the first quarter of 2028 for pulmonary hypertension associated with interstitial lung disease.
1. Trial timelines
IRulya Therapeutics said its fully enrolled, 19-patient bronchiolitis obliterans syndrome trial remains blinded, with dosing continuing; data are expected in the first quarter of 2027. Data from its ongoing 75-patient Phase 2b trial in pulmonary hypertension associated with interstitial lung disease are anticipated in the first quarter of 2028. A Phase 2 trial in sarcoidosis-associated pulmonary hypertension is expected to start in the fourth quarter of 2026, with data anticipated in late 2028.
2. Financing
The company said it raised an oversubscribed $115 million upfront round in May 2026.




